Kate E Oliver1, William E Brady2, Michael Birrer3, David M Gershenson4, Gini Fleming5, Larry J Copeland6, Krishnansu Tewari7, Peter A Argenta8, Robert S Mannel9, Angeles Alvarez Secord10, Jean-Marie Stephan11, David G Mutch12, Frederick B Stehman13, Franco M Muggia14, Peter G Rose15, Deborah K Armstrong16, Michael A Bookman17, Robert A Burger18, John H Farley19. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Naval Medical Center Portsmouth, 620 John Paul Jones Cir, Portsmouth, VA 23708, United States. Electronic address: kate.e.oliver.mil@mail.mil. 2. NRG Oncology Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. Electronic address: bbrady@gogstats.org. 3. Massachusetts General Hospital, Boston, MA 02114, United States. Electronic address: MBIRRER@mgh.harvard.edu. 4. Department of Gynecologic Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, United States. Electronic address: dgershen@mdanderson.org. 5. University of Chicago, 5841 S. Maryland Avenue, Chicago, IL, United States. Electronic address: gfleming@medicine.bsd.uchicago.edu. 6. The Ohio State University, Columbus, OH, United States. Electronic address: larry.copeland@osumc.edu. 7. Obstetrics-Gynecology, University of California, Irvine, Orange, CA, United States. Electronic address: ktewari@uci.edu. 8. University of Minnesota Medical Center, Minneapolis, MN, United States. Electronic address: argenta@umn.edu. 9. University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: robert-mannel@ouhsc.edu. 10. Gynecologic Oncology, Duke Medical Center, Durham, NC, United States. Electronic address: angeles.secord@duke.edu. 11. University of Iowa Hospitals and Clinics, Iowa City, IA, United States. Electronic address: jean-marie-stephan@uiowa.edu. 12. Washington University, United States. Electronic address: mutchd@wudosis.wustl.edu. 13. Indiana University Hospital, Indianapolis, IN, United States. Electronic address: fstehman@iupui.edu. 14. NYU Clinical Cancer Center, New York, NY, United States. Electronic address: franco.muggia@nyumc.org. 15. Cleveland Clinic, Cleveland, OH, United States. Electronic address: rosep@ccf.org. 16. Medical Oncology and Gynecology and Obstetrics, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, United States. Electronic address: ARMSTDE@jhmi.edu. 17. US Oncology Research and Arizona Oncology, Tucson, AZ, United States. Electronic address: Michael.bookman@usoncology.com. 18. University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, United States. Electronic address: Robert.burger@uphs.upenn.edu. 19. Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States. Electronic address: John.farley@chw.edu.
Abstract
PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). RESULTS: There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further. In early stage (I-II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR=1.66 (1.43, 1.91; p<0.001). After adjusting for age and stratifying by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR=1.53 (1.33, 1.76; p<0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly Paclitaxel versus observation in OCCC compared to SOC (p=0.048). CONCLUSIONS: This is one of the largest analyses to date of OCCC treated on multiple cooperative group trials. OCCC histology is more common than SOC in early stage disease. When adjusted for prognostic factors, in early stage patients, PFS was better for OCCC than for SOC; however, in late-stage patients, OCCC was significantly associated with decreased OS. Finally, treatment effect was influenced by histology.
PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). RESULTS: There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further. In early stage (I-II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR=1.66 (1.43, 1.91; p<0.001). After adjusting for age and stratifying by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR=1.53 (1.33, 1.76; p<0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly Paclitaxel versus observation in OCCC compared to SOC (p=0.048). CONCLUSIONS: This is one of the largest analyses to date of OCCC treated on multiple cooperative group trials. OCCC histology is more common than SOC in early stage disease. When adjusted for prognostic factors, in early stage patients, PFS was better for OCCC than for SOC; however, in late-stage patients, OCCC was significantly associated with decreased OS. Finally, treatment effect was influenced by histology.
Authors: B A Goff; R Sainz de la Cuesta; H G Muntz; D Fleischhacker; M Ek; L W Rice; N Nikrui; H K Tamimi; J M Cain; B E Greer; A F Fuller Journal: Gynecol Oncol Date: 1996-03 Impact factor: 5.482
Authors: Linda R Duska; Leslie Garrett; Melissa Henretta; J Stuart Ferriss; Lisa Lee; Neil Horowitz Journal: Gynecol Oncol Date: 2010-03 Impact factor: 5.482
Authors: William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: K Yamaguchi; M Mandai; T Oura; N Matsumura; J Hamanishi; T Baba; S Matsui; S K Murphy; I Konishi Journal: Oncogene Date: 2010-01-11 Impact factor: 9.867
Authors: John K Chan; Deanna Teoh; Jessica M Hu; Jacob Y Shin; Kathryn Osann; Daniel S Kapp Journal: Gynecol Oncol Date: 2008-04-18 Impact factor: 5.482
Authors: Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye Journal: J Natl Cancer Inst Date: 2004-11-17 Impact factor: 13.506
Authors: Koji Matsuo; Hiroko Machida; Shinya Matsuzaki; Brendan H Grubbs; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson; Jason D Wright Journal: Gynecol Oncol Date: 2020-01-15 Impact factor: 5.482
Authors: Shogo Shigeta; Goldie Y L Lui; Reid Shaw; Russell Moser; Kay E Gurley; Grace Durenberger; Rachele Rosati; Robert L Diaz; Tan A Ince; Elizabeth M Swisher; Carla Grandori; Christopher J Kemp Journal: Mol Cancer Ther Date: 2021-01-28 Impact factor: 6.009
Authors: Koji Matsuo; Hiroko Machida; Andrea Mariani; Rachel S Mandelbaum; Gretchen E Glaser; Bobbie S Gostout; Lynda D Roman; Jason D Wright Journal: J Gynecol Oncol Date: 2018-05-04 Impact factor: 4.401
Authors: Hee Yeon Lee; Ji Hyung Hong; Jae Ho Byun; Hee-Jun Kim; Sun Kyung Baek; Jin Young Kim; Ki Hyang Kim; Jina Yun; Jung A Kim; Kwonoh Park; Hyo Jin Lee; Jung Lim Lee; Young-Woong Won; Il Hwan Kim; Woo Kyun Bae; Kyong Hwa Park; Der-Sheng Sun; Suee Lee; Min-Young Lee; Guk Jin Lee; Sook Hee Hong; Yun Hwa Jung; Ho Jung An Journal: Cancer Res Treat Date: 2019-07-12 Impact factor: 4.679